Physician profile
David M Ross, JR.
NPI 1316935166
$1,020.91
in general payments reported to CMS, 2019-2025
18 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $103 · 2021: $139 · 2022: $91.65 · 2023: $211 · 2024: $117 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $522.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $222.40 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $146.90 | 2020-2021 | |
| Alk-Abello, INC | $123.13 | 2025 | Grastek, Odactra, Ragwitek |
| Glaxosmithkline, LLC. | $79.41 | 2019 | |
| Cranial Technologies, INC | $60.72 | 2021-2024 | Doc Band |
| Sanofi Pasteur INC. | $52.24 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $48.90 | 2023-2024 | Qelbree, Qelbree |
| Seqirus USA INC | $44.90 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Ironshore Pharmaceuticals INC. | $42.35 | 2019-2020 | |
| Novo Nordisk INC | $38.42 | 2025 | Ozempic |
| Merck Sharp & Dohme LLC | $37.58 | 2021-2025 | Vaxneuvance, Vaxelis, Enflonsia |
| Pfizer INC. | $26.27 | 2024 | |
| Boston Scientific Corporation | $19.23 | 2019 | |
| Verrica Pharmaceuticals INC. | $18.63 | 2024 | Ycanth |
| Vertical Pharmaceuticals, LLC | $17.38 | 2025 | Relexxii |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $16.42 | 2019 | |
| Shire North American Group INC | $13.85 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.